Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE<sup>®</sup>) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial.
法國患有保留射血分數心衰患者治療中 empagliflozin (JARDIANCE®) 的公共衛生影響和成本效益:基於EMPEROR-Preserved臨床試驗。
Pharmacoecon Open 2024-01-13
Cause-Specific Health Care Costs Following Hospitalization for Heart Failure and Cost Offset With SGLT2i Therapy.
心臟衰竭住院後的特定原因醫療成本及 SGLT2i 治療的成本抵銷。
JACC Heart Fail 2024-05-10
[New perspectives in the diagnosis and treatment of heart failure with preserved ejection fraction (HFpEF)].
心臟衰竭伴隨保留射血分數(HFpEF)的診斷和治療的新觀點。
Rev Med Suisse 2024-05-24
Distinct Profiles and New Pharmacological Targets for Heart Failure with Preserved Ejection Fraction.
心臟衰竭伴保留射血分數的不同特徵及新藥理靶點。
Rev Cardiovasc Med 2024-08-14
The Aging Heart in Focus: The Advanced Understanding of Heart Failure with Preserved Ejection Fraction.
聚焦於老化心臟:對於保留射出分數心衰竭的深入理解。
Ageing Res Rev 2024-10-13
State of precision medicine for heart failure with preserved ejection fraction in a new therapeutic age.
在新療法時代中,心臟衰竭(射血分數保留型)的精準醫療現狀。
ESC Heart Fail 2025-01-23
15-Year trends, predictors, and outcomes of heart failure hospitalization complicating first acute myocardial infarction in the modern percutaneous coronary intervention era.
現代經皮冠狀動脈介入時代首次急性心肌梗塞併發心衰住院的15年趨勢、預測因子及結果。
Eur Heart J Open 2025-03-13